A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer

被引:16
|
作者
Yamamoto, Noboru [1 ]
Tamura, Tomohide [1 ]
Kurata, Takayasu [2 ]
Yamamoto, Nobuyuki [3 ]
Sekine, Ikuo [1 ]
Kunitoh, Hideo [1 ]
Ohe, Yuichiro [1 ]
Saijo, Nagahiro [4 ]
机构
[1] Natl Canc Ctr, Div Internal Med, Chuo Ku, Tokyo 1040045, Japan
[2] Osaka Med Coll, Ctr Canc Chemotherapy, Osaka, Japan
[3] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[4] Natl Canc Ctr Hosp E, Kashiwa, Chiba, Japan
关键词
Nedaplatin; Dose-finding study; Pharmacokinetics; NSCLC; Elderly patient; III RANDOMIZED-TRIAL; PHASE-III; ANTITUMOR-ACTIVITY; CISPLATIN; CHEMOTHERAPY; PLATINUM; CARBOPLATIN; VINORELBINE; JAPAN;
D O I
10.1007/s00280-009-1006-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nedaplatin is a second-generation platinum showing favorable activity against non-small cell lung cancer (NSCLC). Dose-limiting toxicity (DLT) is thrombocytopenia, predicted by creatinine clearance (Ccr). This study was conducted to determine the recommended dose, and evaluate the toxicities, pharmacokinetics and efficacy for elderly NSCLC patients. Patients a parts per thousand yen70 years were stratified into two groups based on renal functions: Group A, Ccr a parts per thousand yen 60 and Group B, 40 a parts per thousand currency sign Ccr < 60. The initial doses were 80 and 60 mg/m(2) in Groups A and B, respectively. The doses were escalated in 20-mg/m(2) increments to 100 mg/m(2) until DLT. Chemotherapy-na < ve 39 elderly patients (Group A/Group B: 22/17) received a total of 83 cycles. Major toxicities were hematological. In Group A, one of the 15 patients at 100 mg/m(2) experienced DLT (neutropenia) and the recommended dose was determined at 100 mg/m(2). In Group B, three of the five patients had DLTs (leukopenia, neutropenia, thrombocytopenia and febrile neutropenia) at 100 mg/m(2), and the recommended dose was determined at 80 mg/m(2). The percentage decreases of neutrophil were well correlated with total and free-Pt AUCs. Partial responses were observed in 13 (33%) of the 39 patients, and 12 of the 13 patients who responded had a squamous cell carcinoma. Nedaplatin was administered simply and feasibly by stratifying renal function and exerted favorable antitumor activity for elderly patients with NSCLC, especially on squamous cell carcinoma.
引用
收藏
页码:79 / 88
页数:10
相关论文
共 50 条
  • [21] Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer
    Hirose, Takashi
    Sugiyama, Tomohide
    Kusumoto, Sojiro
    Shirai, Takao
    Nakashima, Masanao
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Ogura, Keiichi
    Ohnishi, Tsukasa
    Ohmori, Tohru
    Adachi, Mitsuru
    ANTICANCER RESEARCH, 2009, 29 (05) : 1733 - 1738
  • [22] Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug–drug interaction
    Masanori Motonaga
    Noboru Yamamoto
    Yoshinori Makino
    Reiko Ando-Makihara
    Yuichiro Ohe
    Mikihisa Takano
    Yoshikazu Hayashi
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 713 - 721
  • [23] PHASE I/II DOSE-FINDING STUDY OF CRIZOTINIB (CRIZ) IN COMBINATION WITH ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Ou, S. I.
    Govindan, R.
    Eaton, K.
    Argiris, A.
    Otterson, G.
    Robert, F.
    Brega, N.
    Usari, T.
    Tan, W.
    Gutierrez, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 424 - 424
  • [24] Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Ou, Sai-Hong Ignatius
    Govindan, Ramaswamy
    Eaton, Keith D.
    Otterson, Gregory Alan
    Gutierrez, Martin
    Mita, Alain C.
    Argiris, Athanassios
    Brega, Nicoletta
    Usari, Tiziana
    Tan, Weiwei
    Ho, Steffan Nicholas
    Robert, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Burotto, M.
    Felip, E.
    Zvirbule, Z.
    Baranda, L. A. Herraez
    Chanu, P.
    Kshirsagar, S.
    Maiya, V.
    Pozzi, E.
    Restuccia, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S820 - S821
  • [26] Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
    Ranson, M.
    Reck, M.
    Anthoney, A.
    Hanauske, A. -R
    Dean, E.
    Melezinek, I.
    Klingelschmitt, G.
    Kletzl, H.
    Blatter, J.
    Twelves, C.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2233 - 2239
  • [27] DOSE-FINDING STUDIES WITH CARBOPLATIN, IFOSFAMIDE, ETOPOSIDE, AND MESNA IN NON-SMALL CELL LUNG-CANCER
    VANZANDWIJK, N
    HUININK, WWT
    WANDERS, J
    SIMONETTI, G
    DUBBELMAN, R
    FRANKLIN, H
    VANTINTEREN, H
    MCVIE, JG
    SEMINARS IN ONCOLOGY, 1990, 17 (01) : 16 - 19
  • [28] High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study
    Kouroussis, C
    Mavroudis, D
    Kakolyris, S
    Voloudaki, A
    Kalbakis, K
    Souglakos, J
    Agelaki, S
    Malas, K
    Bozionelou, V
    Georgoulias, V
    LUNG CANCER, 2004, 44 (03) : 363 - 368
  • [29] DOSE-FINDING STUDIES WITH CARBOPLATIN, IFOSFAMIDE, ETOPOSIDE AND MESNA IN NON-SMALL CELL LUNG-CANCER
    VANZANDWIJK, N
    HUININK, WWT
    WANDERS, J
    SIMONETTI, G
    DUBBELMAN, R
    FRANKLIN, H
    BROUWER, M
    MCVIE, JG
    IFOSFAMIDE IN THE TREATMENT OF LUNG CANCER, 1989, 35 : 119 - 121
  • [30] Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer
    Maestu, I
    Gómez-Aldaraví, L
    Torregrosa, MD
    Camps, C
    Llorca, C
    Bosch, C
    Gómez, J
    Giner, V
    Oltra, A
    Albert, A
    LUNG CANCER, 2003, 42 (03) : 345 - 354